Aldagen Inc., of Durham, N.C., announced that results from the Phase I/II trial of ALD-301, a stem cell therapy being developed as a treatment for critical limb ischemia, an advanced form of peripheral arterial disease, were published in Catheterization and Cardiovascular Interventions
BrainStorm Inc., of New York, and Hadasit, the technology transfer company of the Hadassah Medical Organization in Petach Tikvah, Israel, said Israeli regulators approved a Phase I/II study of NurOwn, BrainStorm's autologous stem cell therapy in amyotrophic lateral sclerosis...A total of 24 patients, 12 in advanced stage of the disease and 12 in early stage, will be transplanted with stem cells derived from their own bone marrow and treated with BrainStorm's NurOwn technology
Millennium, of Cambridge, Mass., a unit of the Takeda Oncology Co., said results of a randomized Phase III trial that investigated the effect of consolidation with single-agent Velcade (bortezomib) for Injection in newly diagnosed multiple myeloma patients after autologous stem cell transplant showed significant improvements in response rates and progression-free survival, while the overall survival rate was 87 percent in both arms after a median follow-up of 27 months
Stem Cell Therapeutics Corp., of Calgary, Alberta, enrolled the first patient in an open-label Phase IIa traumatic brain injury (TBI) trial testing the safety profile of NTx-428, a human chorionic gonadotropin and epoeitin alfa therapy, when administered to patients who have sustained a TBI
Advanced Cell Technology Inc., of Marlborough, Mass., said that the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA) has received institutional review board approval to be a site for its Phase I/II trials for Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells
Tarix Pharmaceuticals Ltd., of Brookline, Mass., enrolled its first patient in a Phase I trial of TXA-127 for stimulation of hematopoietic precursor cells in bone marrow following double cord blood stem cell transplant
Advanced Cell Technology Inc., of Marlborough, Mass., filed a clinical trial application with the European Medicines and Healthcare products Regulatory Agency seeking clearance for a Phase I/II study of retinal pigment epithelial (RPE) cells derived from human embryonic stem cells to treat Stargardt's macular dystrophy
StemCells Inc., of Palo Alto, Calif., discontinued a Phase Ib trial of HuCNS-SCA human neuronal stem cells in neuronal ceroid lipofuscinosis (NCL) due to lack of patient accrual
Cardio3 BioSciences SA, of Mont-Saint-Guibert, Belgium, reported detailed Phase II data showing that C3BS-CQR-1 (C-Cure), its stem cell therapy for ischemic cardiomyopathy, resulted in improved heart function and exercise capacity in heart failure patients at six months following treatment
Stemedica Cell Technologies Inc., of San Diego, said its ischemic adult allogeneic mesenchymal stem cells were used successfully to treat the first patient in an ischemic stroke study...A total of 35 patients will be enrolled in the study, which is designed to determine tolerance and therapeutic outcomes for the intravenously delivered stem cells
StemCells Inc., of Palo Alto, Calif., started a Phase I/II trial of its HuCNS-SC human neural stem cells in chronic spinal cord injury in patients with both complete and incomplete degrees of paralysis who are three months to 12 months post-injury
StemCells Inc., of Palo Alto, Calif., said the fourth and final patient in its Phase I trial in Pelizaeus-Merzbacher disease (PMD) was transplanted with the company's HuCNS-SC cells (purified human neural stem cells...The trial is the first to evaluate neural stem cells as a potential treatment for a myelination disorder
Magellan MAR01 is designed for a rapid, closed-system concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells
Cytori Therapeutics Inc., of San Diego, received approval from the Netherlands to start a pivotal European trial, designated ADVANCE, to test adipose-derived stem and regenerative stem cells processed by the Celution One System in patients with acute heart attacks
ET is a chronic disorder that arises in the hematopoietic stem cells in the bone marrow...The leukemic stem cells produce aberrant clones of platelet-forming cells, which results in increased numbers of circulating platelets
Aldagen Inc., of Durham, N.C., announced that results from the Phase I/II trial of ALD-301, a stem cell therapy being developed as a treatment for critical limb ischemia, an advanced form of peripheral arterial disease, were published in Catheterization and Cardiovascular Interventions